



(51) International Patent Classification:

A61P 9/00 (2006.01) A61P 19/02 (2006.01)

A61P 13/12 (2006.01) A61P 29/00 (2006.01)

A61P 17/06 (2006.01) A61P 37/02 (2006.01)

(21) International Application Number:

PCT/US2020/038084

(22) International Filing Date:

17 June 2020 (17.06.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/862,186 17 June 2019 (17.06.2019) US

(71) Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH [US/US]; 200 First Street SW, Rochester, Minnesota 55905 (US).

(72) Inventor: TANEJA, Veena; 4529 Cornwall Dr. N.W., Rochester, Minnesota 55901-3424 (US).

(74) Agent: MAIZE, Kimberly M. et al.; P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(54) Title: PREVOTELLA PREPARATIONS AND TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND OTHER LUNG CONDITIONS




Figure 1

(57) Abstract: This document provides methods and materials related to the treatment of a lung condition, such as chronic obstructive pulmonary disease (COPD), using a composition containing live *Prevotella* (e.g., *P. histicola* and/or *P. melaninogenica*), dead (or killed) *Prevotella* (e.g., *P. histicola* and/or *P. melaninogenica*), components of *Prevotella* (e.g., *P. histicola* and/or *P. melaninogenica*), vesicles (e.g., OMVs) of *Prevotella* (e.g., *P. histicola* and/or *P. melaninogenica*), or a combination thereof. For example, methods and materials for using a composition containing live *Prevotella* (e.g., *P. histicola* and/or *P. melaninogenica*), dead (or killed) *Prevotella* (e.g., *P. histicola* and/or *P. melaninogenica*), components of *Prevotella* (e.g., *P. histicola* and/or *P. melaninogenica*), vesicles (e.g., OMVs) of *Prevotella* (e.g., *P. histicola* and/or *P. melaninogenica*), or a combination thereof to treat a lung condition, such as COPD, are provided.

Published:

— *with international search report (Art. 21(3))*